ProfileGDS5678 / 1423652_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 84% 85% 85% 85% 87% 83% 79% 83% 83% 85% 86% 85% 86% 88% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.2125484
GSM967853U87-EV human glioblastoma xenograft - Control 26.3992385
GSM967854U87-EV human glioblastoma xenograft - Control 36.4623485
GSM967855U87-EV human glioblastoma xenograft - Control 46.5591685
GSM967856U87-EV human glioblastoma xenograft - Control 56.7184987
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.922283
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.3256879
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.1184683
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.1341783
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.4426785
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.460686
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.4789385
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.5022586
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.7964588